Sign in to view content

Real-world U.S. outcomes of anti-VEGF therapy in diabetic macular edema

Thomas A. Ciulla, MD, MBA, FASRS

Video
Published 2017

Related

Brolucizumab for Neovascular AMD: The 2 Year HAWK and HARRIER Results
Pravin U. Dugel, MD
Updates from the Field
2018
Process Mapping and Activity Based Costing of the Intravitreal Injection Procedure
Christina Y Weng, MD, MBA, FASRS
Annual Meeting Talks
2019
Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more